6.21

0.32% -0.02

Emergent Biosolutions Inc (EBS)

Overview News Price History Option Chain Discussions Forecast

Emergent Biosolutions Inc stock is traded at $6.21, with a volume of 998.36K. It is down -0.32% in the last 24 hours and down -17.97% over the past month. Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Previous Close:

$6.23

Open:

$6.26

24h Volume:

998.36K

Relative Volume:

0.97

Market Cap:

$318.41M

Revenue:

$676.80M

Net Income/Loss:

$-8.60M

P/E Ratio:

-21.95

EPS:

-0.2829

Net Cash Flow:

$135.40M

1W Performance:

+5.08%

1M Performance:

-17.97%

6M Performance:

-29.19%

1Y Performance:

-18.61%

1-Day Range:

$6.14

$6.30

1-Week Range:

$5.80

$6.60

52-Week Range:

$4.36

$14.06

Emergent Biosolutions Inc Stock (EBS) Company Profile

Name

Emergent Biosolutions Inc

Sector

Healthcare (1074)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

240-631-3200

Address

300 PROFESSIONAL DR, GAITHERSBURG, MD

Employee

900

Twitter

@emergentbiosolu

Next Earnings Date

2026-08-05

Latest SEC Filings

EBS's Discussions on Twitter

Compare EBS vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EBS Emergent Biosolutions Inc	6.21	247.14M	676.80M	-8.60M	135.40M	-0.2829
TAK Takeda Pharmaceutical Co Adr	18.45	57.90B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.36	42.89B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.60	43.41B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	75.81	31.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	487.61	22.35B	3.17B	1.29B	1.01B	27.09

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-22-24	Initiated	Rodman & Renshaw	Buy
Mar-07-24	Upgrade	The Benchmark Company	Hold → Buy
Nov-20-23	Resumed	JP Morgan	Underweight
Aug-29-23	Downgrade	The Benchmark Company	Buy → Hold
Apr-10-23	Upgrade	The Benchmark Company	Hold → Buy
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-10-22	Downgrade	The Benchmark Company	Buy → Hold
Apr-29-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-20-22	Upgrade	The Benchmark Company	Hold → Buy
Nov-08-21	Downgrade	The Benchmark Company	Buy → Hold
May-05-21	Downgrade	Argus	Buy → Hold
Apr-07-21	Initiated	The Benchmark Company	Buy
Feb-24-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-19-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-14-20	Resumed	JP Morgan	Neutral
Jul-31-20	Reiterated	Chardan Capital Markets	Buy
Sep-12-19	Initiated	Guggenheim	Buy
Sep-04-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-02-18	Upgrade	Goldman	Neutral → Buy
Aug-03-18	Reiterated	Chardan Capital Markets	Buy
Jun-13-18	Initiated	Argus	Buy
Apr-25-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jan-24-18	Initiated	Goldman	Neutral
Jan-16-18	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	Singular Research	Buy
Apr-15-16	Initiated	Chardan Capital Markets	Buy
Mar-28-16	Initiated	Singular Research	Buy
Feb-19-16	Initiated	Wells Fargo	Outperform
May-15-14	Initiated	Summer Street Research	Buy
May-31-11	Reiterated	WBB Securities	Strong Buy
Jan-10-11	Reiterated	Wedbush	Outperform
Nov-05-10	Reiterated	Wedbush	Outperform
Aug-18-10	Upgrade	WBB Securities	Buy → Strong Buy
Aug-06-10	Reiterated	Caris & Company	Buy

View All

Emergent Biosolutions Inc Stock (EBS) Latest News

Aug 21, 2026

EBS Reinstated by JP Morgan -- Current Rating Underweight - GuruFocus

Aug 21, 2026

2026-08-21 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Stockholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse

Aug 21, 2026

JPMorgan Chase & Co. Begins Coverage on Emergent Biosolutions (NYSE:EBS) - MarketBeat

Aug 21, 2026

EBS Looks 11.9% Undervalued on GF Value™ Despite Underweight Rat - GuruFocus

Aug 21, 2026

Aug 20, 2026

Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits

Aug 20, 2026

Aug 19, 2026

Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus

Aug 19, 2026

Emergent (EBS) Price: Gains 4.94% to Reach $4.89 at the Close; Immediate View: the Near-Term Reference Band Stretches From $4.65 to $5.13 on the DayPrice Target - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Emergent BioSolutions Balances Q2 Beat With Tough Outlook - The Globe and Mail

Aug 18, 2026

S&P downgrades Emergent BioSolutions outlook on competition - Investing.com

Aug 18, 2026

Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire

Aug 18, 2026

Emergent BioSolutions (EBS) Holds Above Support as Shares Slip 0.33%Volume Oscillator - vinanet.vn

Aug 18, 2026

Aug 17, 2026